Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia

Current Oncology

View Publication Info
 
 
Field Value
 
Title Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia
 
Creator Banerji, V.
Aw, A.
Robinson, S.
Doucette, S.
Christofides, A.
Sehn, L.H.
 
Subject Bruton tyrosine kinase inhibitors
chronic lymphocytic leukemia
untreated disease
frontline therapy
first-line therapy
 
Description Chronic lymphocytic leukemia (CLL) is the most commonly diagnosed adult leukemia in Canada. Biologic heterogeneity of CLL can be observed between patients which results in variable disease trajectory and response to therapy. Notably, patients with high-risk features such as the presence of deletions in chromosome 17p, aberrations in the TP53 gene, or unmutated immunoglobulin heavy chain variable region genes have inferior outcomes and response to standard chemoimmunotherapy compared to patients without these features. Novel agents which target the B cell receptor signalling pathway, such as Bruton’s tyrosine kinase (BTK) inhibitors have demonstrated clinical efficacy and safety in patients with treatment-naïve CLL, particularly in those with high-risk features. However, due to the current lack of head-to-head trials comparing BTK inhibitors, selection of the optimal BTK inhibitor for patients with CLL is unclear and requires the consideration of multiple factors. This review focuses on the efficacy, safety, and pharmacological features of the BTK inhibitors that are approved or are under clinical development and discusses the practical considerations for the use of these agents in the Canadian treatment landscape.
 
Publisher Multimed Inc.
 
Date 2020-08-10
 
Type info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
 
Format application/pdf
text/html
 
Identifier http://www.current-oncology.com/index.php/oncology/article/view/6795
10.3747/co.27.6795
 
Source Current Oncology; Vol. 27 No. 6 (2020)
1718-7729
1198-0052
 
Language eng
 
Relation http://www.current-oncology.com/index.php/oncology/article/view/6795/9657
http://www.current-oncology.com/index.php/oncology/article/view/6795/9715
 
Rights Copyright (c) 2020 Multimed Inc.
 

Contact Us

The PKP Index is an initiative of the Public Knowledge Project.

For PKP Publishing Services please use the PKP|PS contact form.

For support with PKP software we encourage users to consult our wiki for documentation and search our support forums.

For any other correspondence feel free to contact us using the PKP contact form.

Find Us

Twitter

Copyright © 2015-2018 Simon Fraser University Library